Cargando…

Development and validation of analytical methods /

The need to validate an analytical or bioanalytical method is encountered by analysts in the pharmaceutical industry on an almost daily basis, because adequately validated methods are a necessity for approvable regulatory filings. What constitutes a validated method, however, is subject to analyst i...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Riley, Christopher M., Rosanske, Thomas W.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Tarrytown, N.Y. : Pergamon, 1996.
Edición:1st ed.
Colección:Progress in pharmaceutical and biomedical analysis ; v. 3.
Temas:
Acceso en línea:Texto completo
Texto completo
Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 SCIDIR_ocn162565745
003 OCoLC
005 20231117014911.0
006 m o d
007 cr cn|||||||||
008 070806s1996 nyua ob 001 0 eng d
040 |a OPELS  |b eng  |e pn  |c OPELS  |d DEBSZ  |d OPELS  |d OCLCQ  |d N$T  |d YDXCP  |d IDEBK  |d E7B  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCF  |d CHVBK  |d KIJ  |d OCLCQ  |d UAB  |d PHUST  |d OCLCQ  |d CASUM  |d OCLCA  |d STF  |d D6H  |d OCLCO  |d OCLCQ  |d OCLCA  |d LEAUB  |d OCLCO  |d OL$  |d OCLCA  |d OCLCQ  |d OCLCO  |d COM  |d OCLCO  |d OCLCQ  |d OCLCO 
019 |a 175289247  |a 647652750  |a 742285492  |a 815530640  |a 823109262  |a 823829779  |a 823899485  |a 824090757  |a 824138417  |a 989203276  |a 1011231491  |a 1027483177  |a 1035707145  |a 1119427619 
020 |a 9780080427928 
020 |a 0080427928 
020 |a 9780080530352  |q (electronic bk.) 
020 |a 0080530354  |q (electronic bk.) 
020 |a 1281053899 
020 |a 9781281053893 
035 |a (OCoLC)162565745  |z (OCoLC)175289247  |z (OCoLC)647652750  |z (OCoLC)742285492  |z (OCoLC)815530640  |z (OCoLC)823109262  |z (OCoLC)823829779  |z (OCoLC)823899485  |z (OCoLC)824090757  |z (OCoLC)824138417  |z (OCoLC)989203276  |z (OCoLC)1011231491  |z (OCoLC)1027483177  |z (OCoLC)1035707145  |z (OCoLC)1119427619 
050 4 |a RS189  |b .P442 1996eb 
060 4 |a W1  |b PR677LM v.3 1996 
060 4 |a QV 25  |b P5353 1996 
072 7 |a MED  |x 023000  |2 bisacsh 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a MED  |x 072000  |2 bisacsh 
072 7 |a MED  |x 058170  |2 bisacsh 
072 7 |a PNF  |2 bicssc 
082 0 4 |a 615/.1901  |2 22 
245 0 0 |a Development and validation of analytical methods /  |c edited by Christopher M. Riley and Thomas W. Rosanske. 
250 |a 1st ed. 
260 |a Tarrytown, N.Y. :  |b Pergamon,  |c 1996. 
300 |a 1 online resource (x, 352 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Progress in pharmaceutical and biomedical analysis ;  |v v. 3 
520 |a The need to validate an analytical or bioanalytical method is encountered by analysts in the pharmaceutical industry on an almost daily basis, because adequately validated methods are a necessity for approvable regulatory filings. What constitutes a validated method, however, is subject to analyst interpretation because there is no universally accepted industry practice for assay validation. This book is intended to serve as a guide to the analyst in terms of the issues and parameters that must be considered in the development and validation of analytical methods. In addition to the critical issues surrounding method validation, this book also deals with other related factors such as method development, data acquisition, automation, cleaning validation and regulatory considerations. The book is divided into three parts. Part One, comprising two chapters, looks at some of the basic concepts of method validation. Chapter 1 discusses the general concept of validation and its role in the process of transferring methods from laboratory to laboratory. Chapter 2 looks at some of the critical parameters included in a validation program and the various statistical treatments given to these parameters. Part Two (Chapters 3, 4 and 5) of the book focuses on the regulatory perspective of analytical validation. Chapter 3 discusses in some detail how validation is treated by various regulatory agencies around the world, including the United States, Canada, the European Community, Australia and Japan. This chapter also discusses the International Conference on Harmonization (ICH) treatment of assay validation. Chapters 4 and 5 cover the issues and various perspectives of the recent United States vs. Barr Laboratories Inc. case involving the retesting of samples. Part Three (Chapters 6 - 12) covers the development and validation of various analytical components of the pharmaceutical product development process. This part of the book contains specific chapters dedicated to bulk drug substances and finished products, dissolution studies, robotics and automated workstations, biotechnology products, biological samples, analytical methods for cleaning procedures and computer systems and computer-aided validation. Each chapter goes into some detail describing the critical development and related validation considerations for each topic. This book is not intended to be a practical description of the analytical validation process, but more of a guide to the critical parameters and considerations that must be attended to in a pharmaceutical development program. Despite the existence of numerous guidelines including the recent attempts by the ICH to be implemented in 1998, the practical part of assay validation will always remain, to a certain extent, a matter of the personal preference of the analyst or company. Nevertheless, this book brings together the perspectives of several experts having extensive experience in different capacities in the pharmaceutical industry in an attempt to bring some consistency to analytical method development and validation. 
505 0 |a Section headings and papers: List of Contributors. Introduction. Basic Concepts. Assay validation and inter-laboratory transfer (E. McGonigle). Statistical parameters and analytical figures of merit (C.M. Riley). Regulatory Considerations. Overview of worldwide regulations (I.E. Davidson). Issues related to United States v. Barr Laboratories Inc. (C.L. Burgess). Judge Wolin's interpretations of current good manufacturing practice issues contained in the court's ruling in the United States v. Barr Laboratories (R.J. Davis). Specific Methods and Applications. Bulk drug substances and finished products (P.K. Hovsepian). Dissolution studies (T.W. Rosanske, C.K. Brown). Robotics and automated workstations (J.J. Tomlinson). Biotechnology products (G.S. Srivatsa). Biological samples (K.A. Selinger). Analytical methods for cleaning procedures (T.M. Rossi, R.R. Ryall). Computer systems and computer-aided validation (J.G. Liscouski). Index. 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record. 
650 0 |a Drugs  |x Analysis  |x Methodology. 
650 1 2 |a Chemistry, Pharmaceutical  |x methods  |0 (DNLM)D002626Q000379 
650 2 2 |a Pharmaceutical Preparations  |x analysis  |0 (DNLM)D004364Q000032 
650 6 |a M�edicaments  |0 (CaQQLa)201-0036381  |x Analyse  |0 (CaQQLa)201-0036381  |x M�ethodologie.  |0 (CaQQLa)201-0379663 
650 7 |a MEDICAL  |x Drug Guides.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacy.  |2 bisacsh 
650 7 |a MEDICAL  |x Nursing  |x Pharmacology.  |2 bisacsh 
650 7 |a Drugs  |x Analysis  |x Methodology  |2 fast  |0 (OCoLC)fst00898771 
653 0 |a Drugs  |a Chemical analysis 
700 1 |a Riley, Christopher M. 
700 1 |a Rosanske, Thomas W. 
776 0 8 |i Print version:  |t Development and validation of analytical methods.  |b 1st ed.  |d Tarrytown, N.Y. : Pergamon, 1996  |z 0080427928  |z 9780080427928  |w (DLC) 96033800  |w (OCoLC)34357139 
830 0 |a Progress in pharmaceutical and biomedical analysis ;  |v v. 3. 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780080427928  |z Texto completo 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/publication?issn=14643456&volume=3  |z Texto completo 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/bookseries/14643456/3  |z Texto completo